Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.
Paul V. O’Donnell, MD, PhD, from the Seattle Cancer Care Alliance, discusses a study examining alternative donor transplant methods for patients with hematologic malignancies.
Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive’s Strategic Alliance Partnership Program.
> Web Exclusives - April 2nd, 2013
An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.
Patients with cancer who have lower incomes are less likely to participate in clinical trials, according to a large national survey.